Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...
A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback